Benchmark created for FSG (flexible sigmoidoscopy) colorectal screening
This article was originally published in Clinica
The largest colorectal cancer screening study to date has produced benchmark data for what could be expected from the large-scale use of flexible sigmoidoscopy (FSG) as a screening tool for the disease in the US.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.